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ImmunotherapyImmunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity (ADCC).
Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment for locally advanced
and recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic
colorectal cancer (CRC). Here we review evidence regarding the clinical relevance of cetuximab-mediated
ADCC and other immune functions and provide a biological rationale concerning why this property posi-
tions cetuximab as an ideal partner for immune checkpoint inhibitors (ICIs) and other emerging
immunotherapies. We performed a nonsystematic review of available preclinical and clinical data involv-
ing cetuximab-mediated immune activity and combination approaches of cetuximab with other
immunotherapies, including ICIs, in SCCHN and CRC. Indeed, cetuximab mediates ADCC activity in the
intratumoral space and primes adaptive and innate cellular immunity. However, counterregulatory
mechanisms may lead to immunosuppressive feedback loops. Accordingly, there is a strong rationale
for combining ICIs with cetuximab for the treatment of advanced tumors, as targeting CTLA-4, PD-1,
and PD-L1 can ostensibly overcome these immunosuppressive counter-mechanisms in the tumor
microenvironment. Moreover, combining ICIs (or other immunotherapies) with cetuximab is a promising
strategy for boosting immune response and enhancing response rates and durability of response.
Cetuximab immune activity—including, but not limited to, ADCC—provides a strong rationale for its com-
bination with ICIs or other immunotherapies to synergistically and fully mobilize the adaptive and innate
immunity against tumor cells. Ongoing prospective studies will evaluate the clinical effect of these com-
bination regimens and their immune effect in CRC and SCCHN and in other indications.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In recent years, emerging tools for targeting tumor cells via the
immune system have shifted oncologists’ focus away from cyto-toxic chemicals and onto immunotherapy. Almost all of the func-
tions of the immune system may have therapeutic implications,
and many have already been widely studied in experimental
models and in humans. Among them, antibody-dependent cell-
mediated cytotoxicity (ADCC) appears to be a promising field of
investigation.
Years of preclinical and clinical work have shown that
immunoglobulin (Ig) G1 monoclonal antibodies (mAbs) have the
highest capability for stimulating ADCC compared with other
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treated with IgG1-based therapies [1–3]. In oncology, several com-
monly used therapeutic mAbs have the IgG1 backbone and are
shown to stimulate ADCC, including trastuzumab (an anti–human
epidermal growth factor receptor [EGFR] 2 [HER2] mAb, widely
used in breast cancer) [4], necitumumab (an anti-EGFR mAb used
in lung cancer), rituximab (an anti–cluster of differentiation [CD]
20 mAb used in non-Hodgkin lymphoma and chronic lymphocytic
leukemia) [4], and cetuximab (an anti-EGFR mAb used in RASwild-
type metastatic colorectal cancer [mCRC] and locally advanced and
recurrent and/or metastatic squamous cell carcinoma of the head
and neck [LA and R/M SCCHN]) [4]. These mAbs have the IgG1
backbone and are thought to owe part of their antitumor activity
to modulation of immune cells, especially when treating immuno-
logically ‘‘hot” tumors [5–8]. Novel immunostimulatory therapies
have made possible a new approach to combination therapy with
IgG1 isotype mAbs such as cetuximab [9], namely, the synergizing
of ADCC (and other possible immune actions) with additional
immunomodulatory treatments.
With the emergence of immune checkpoint inhibitors (ICIs) tar-
geting programmed death-ligand 1 (PD-L1), its receptor PD-1, and
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)—along with
other immunotherapies—the possibilities for combining various
immunostimulatory drugs are now being explored in clinical trials.
ICIs and other immunotherapies have been developed and are
being tested in many indications. However, in SCCHN and CRC,
ICI monotherapy seems associated with relatively low overall
response rates (ORRs; 18% in R/M SCCHN and  0% in
chromosome-unstable CRC [representing the majority of cases]
[10–12]) and a lack of dramatic responses in many patients [13]
compared with the more impressive ORRs of up to 57% in other
advanced/pretreated indications, such as non-small cell lung can-
cer and melanoma [14–16]. Combination immunotherapy repre-
sents a promising approach to boost antitumor activity in
indications such as SCCHN and CRC as well as any other indications
suitable for immunomodulatory therapy.Fig. 1. Rationale for combination therapy. Complementary and synergistic activities
advantages (in black) and challenges (in red) associated with the use of cetuximab and IC
mobilization of Treg), and thus, the combination of cetuximab and ICIs may yield high le
ADCC, antibody-dependent cell-mediated cytotoxicity; EGFR, epidermal growth factor re
rate; PD-L1, programmed death-ligand 1; RR, response rate; Treg, regulatory T cells; TTR,
the reader is referred to the web version of this article.)As cetuximab is already an established standard of care in both
SCCHN and CRC, in this manuscript we focus on cetuximab as a key
example of an IgG1 therapy with clinically relevant ADCC and
related immunomodulatory activities in order to explore its poten-
tial for combination with immunotherapies such as ICIs. We
describe the detailed mechanisms for cetuximab-driven immune
actions and summarize the available evidence for these effects in
CRC and SCCHN. In addition, we provide the scientific rationale
for combining ICIs/other immunotherapies with cetuximab to syn-
ergistically mobilize the adaptive and innate immune systems
against tumor cells, thereby potentially improving upon durable
responsiveness and patient survival in challenging indications such
as SCCHN and mCRC (Fig. 1). These principles of combining
immunostimulatory therapies are also likely to be of interest in
indications beyond CRC and SCCHN.Mechanism of cetuximab-driven immune activity
ADCC is a biological process that contributes to the targeting
and killing of antibody-coated cells by immune cells and is trig-
gered by IgG1 isotype mAbs in the presence of natural killer (NK)
cells. Cetuximab has strong immunomodulatory activity, in part
via ADCC, in addition to inhibition of the EGFR intracellular signal-
ing pathway [17–20]. Briefly, cetuximab stimulates ADCC when its
constant region, Fc, binds to a receptor found on NK cells (activat-
ing Fc receptor CD16/FccRIII) [21], resulting in NK cell activation.
Active NK cells can carry out their own lytic activity on tumor cells,
and each active NK cell can serially lyse multiple target cells [22].
This is the process of ADCC. Importantly, other immune activity
also results from the activation of NK cells via the interaction with
the Fc region of an IgG1 isotype mAb. NK cells appear to use
interferon-c (IFNc) and various cytokines to facilitate crosstalk
with dendritic cells (DCs) and other immune cells (eg, macro-
phages, other NK cells). Activated NK cells that lyse tumor cells
lead to the release of tumor antigens, which can be cross-of cetuximab and ICI-based therapies. This Venn diagram describes the known
Is. The two therapies have complementary properties (eg, when considering TTR and
vels of immunostimulation and a durable response in a high percentage of patients.
ceptor; ICI, immune checkpoint inhibitor; NK, natural killer; ORR, overall response
time to response. (For interpretation of the references to color in this figure legend,
Fig. 2A. Mechanism of cetuximab-mediated immune activity. The binding of cetuximab to EGFR and to the CD16 receptor on NK and dendritic cells sets off multiple immune
actions that can lead to tumor cell targeting and death, including ADCC (innate immunity) and T cell priming (adaptive immunity). CD, cluster of differentiation; CXCL,
chemokine (C-X-C motif) ligand; CXCR, C-X-C chemokine receptor; EGFR, epidermal growth factor receptor; F, phenylalanine; IgG1, immunoglobulin G1; IFNc, interferon-c;
IL, interleukin; NK, natural killer; V, valine.
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tumor cell killing activity [19,23–28]. Thus, the binding of an IgG1
isotype mAb to its target and to the CD16 receptor on NK cells can
stimulate the priming and activation of both immune effector cells
of the innate and adaptive immune systems. Additionally,
cytokine-mediated crosstalk with macrophages and other immune
cells is essential for bringing into the intratumoral space additional
active, cytotoxic T cells, which can then carry out lytic activity on
tumor cells and thus generate additional tumor antigens and fur-
ther stimulate a long-term immune response [29,30]. Thus, cetux-
imab stimulates immunogenic tumor cell death, involving multiple
cytotoxic immune cell types [29,30]. An overview of the mecha-
nism for mounting a cetuximab-driven, antitumor immune
response is shown in Fig. 2A, and current preclinical and clinical
evidence for cetuximab-driven ADCC and other mechanisms is
summarized in Tables 1 and 2.Cetuximab elicits tumor cell apoptosis via EGFR inhibition and
additional tumor cell death mediated by the distinct mAb-
dependent immune actions (cytotoxic T cell recruitment and prim-
ing), including mechanisms specific to its IgG1 backbone (NK cell-
mediated ADCC) [6,24,31–33]. The existence of an IgG2 isotype
anti-EGFR mAb, panitumumab (which does not trigger NK cell–
mediated ADCC), has offered researchers the unique opportunity
to compare the effects of mAb-mediated EGFR inhibition +/- the
attribute of NK cell stimulation. The immunologic distinction
between these 2 mAbs has been conclusively demonstrated
ex vivo: when all other conditions are equal and optimized, an
IgG1 anti-EGFR mAb (cetuximab) stimulates NK cell–mediated
ADCC and thus increases immune-mediated tumor cell death to a
greater level than does an IgG2 anti-EGFR mAb [19,29,31,34]. This
difference in activity may account for the differential efficacy of the
2 mAbs sometimes observed in human patients; for example, in
Table 1
Preclinical evidence for cetuximab-mediated immune effects.
Relevant findings Indication
Jie et al.: In ex vivo assays, ipilimumab can suppress CTLA-4+ Treg activity and restore cetuximab-driven, NK cell–mediated ADCC [42] SCCHN
Khort et al.: Cetuximab treatment is associated with increased expression of CD137 on isolated human NK cells; treating with a CD137–agonistic mAb in
addition to cetuximab led to increased cytotoxicity. Treating with this combination therapy led to complete tumor resolution in a murine xenograft
model [60]
CRC
Kubach et al.:High-dose IgG1 anti–EGFR antibodies induce immune-independent tumor regression, but at low doses, they induce tumor cell killing through
CD8+ T cell–mediated ADCC [115]
SCCHN
Trivedi et al.: Panitumumab and cetuximab inhibit the EGFR to a similar extent; however, cetuximab is more effective at triggering NK cell–mediated ADCC
[19]
SCCHN
Trotta et al.: Patients carrying the CD16 genotypes 158 V/V and 158 F/V experienced significantly higher ADCC activity after cetuximab treatment than did
patients carrying the 158 F/F genotype. Additionally, patients carrying the V allele had longer PFS than patients who did not, although no significant
difference in OS was observed [3]
CRC
Yang et al.: Cetuximab antitumor activity is more potent in the presence of adaptive immunity components, including CD8+ T cells [116] SCCHN
ADCC mechanism
Chen et al.: In a murine xenograft model, cetuximab increased NK cell–mediated ADCC activity against colorectal cancer cells with high EGFR expression
[117]
CRC
Correale et al.: 5-FU, irinotecan, and gemcitabine individually and in combination can induce increased EGFR expression in colorectal tumor cells and
increase susceptibility to cetuximab-driven ADCC [118]
CRC
Levy et al.: HLA-E can inhibit cetuximab-driven ADCC and thus interfere with cetuximab-driven immune cell–mediated lytic activity against tumor cells
[119]
CRC
Pozzi et al.: Cetuximab in combination with chemotherapy induces immunogenic cell death in EGFR-expressing colorectal cancer cells [30] CRC
ADCC modulation
Kondo et al.: EGFR expression levels on tumor cells may influence sensitivity to cetuximab-driven ADCC [120] SCCHN
Nakadate et al.: Cetuximab-driven, perforin-independent ADCC was observed against colorectal cancer cells only if they have wild-type KRAS status [121] CRC
Taylor et al.: Cetuximab-driven ADCC can kill SCCHN cells in vitro, and is highest in patients carrying a V allele at position 158 on CD16 [122] SCCHN
Veluchamy et al.: Cetuximab enhances NK cell–mediated lytic activity on EGFR-expressing tumor cells in a CD16–, but not RAS mutational status–
dependent manner [43]
CRC
Seo et al.: Cetuximab enhances peripheral mononuclear cell–mediated ADCC on EGFR-expressing tumor cells independently of RAS or BRAF mutational
status–dependent manner [123]
CRC
Srivastava et al.: Cetuximab in combination with CD137 agonist mAb urelumab led to increased NK cell survival, DC maturation, and tumor antigen cross-
presentation in patients in a phase 1b study [44]
SCCHN
5-FU, 5-fluorouracil; ADCC, antibody-dependent cell-mediated cytotoxicity; CD, cluster of differentiation; CRC, colorectal cancer; CTLA-4, cytotoxic T-lymphocyte-associated
protein 4; DC, dendritic cell; EGFR, epidermal growth factor receptor; F, phenylalanine; HLA, human leukocyte antigen; Ig, immunoglobulin; mAb, monoclonal antibody; NK,
natural killer; OS, overall survival; PFS, progression-free survival; SCCHN, squamous cell carcinoma of the head and neck; Treg, regulatory T cell; V, valine.
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(resulting in overall survival benefits) in SCCHN in combination
with radiotherapy or platinum-based chemotherapy, while panitu-
mumab was not able to demonstrate a statistically positive differ-
ence [35–38]. Tumor-antigen binding (i.e., to EGFR) and ADCC
stimulation are interlinked processes, a phenomenon that may
explain why ADCC appears highly relevant for antitumor efficacy
in SCCHN (extremely high tumor EGFR expression, i.e., more avail-
able targets). Similarly, there are populations of patients with
mCRC who may benefit more from an IgG1-based therapy than
from an IgG2, potentially due to an increased sensitivity to
immunostimulation, including the mechanism of ADCC; discussion
follows. Indeed, this may be the case for other indications with
high tumor EGFR expression, such as lung cancer [39], or for any
patient with cancer who has high basal ADCC activity [2,40].
Experimentally, ex vivo and in vitro assays with patients’ puri-
fied lymphocyte populations [3,19,25,26,41] from the tumor
microenvironment and the peripheral blood are used to directly
observe NK cell activation and lytic activity [31,42,43]. Indirect
measurements are performed using markers on circulating and
tumor-infiltrating T cells, NK cells, and DCs, as well as cytokine
levels in the plasma [1,44], including expression of activating
receptors such as CD16, CD107a, CD137, NK group 2 member D
(NKG2D), and NK cell p46–related protein (NKp46) receptors
[26,42,45]. Furthermore, expression of perforin and granzyme B,
the functional molecules of NK cell lytic activity, also indicates high
tumor cell killing, and their depletion can lead to the eventual
dampening of lytic activity [22,42,45]. Conversely, increased levels
of transforming growth factor b (TGFb) or interleukin 10 (IL-10) in
plasma, increased expression of CTLA-4 and PD-1 on T cells, PD-L1
expression on tumor or immune cells, or NK group 2 member A
(NKG2A) receptor expression on NK cells are considered indicators
of immunosuppression, and they work to downregulate NK andeffector T cell cytotoxic activity [25,42,45–47]. Finally, increased
frequency of CD4+/forkhead box p3+ (CD4+/Foxp3+) regulatory T
cells (Treg), especially in the tumor microenvironment, is associ-
ated with suppressed NK lytic activity and reduction of the
immune response markers mentioned previously [25,42,46,48],
similarly suppressing ADCC activity. The abundance of regulatory
mechanisms underline the relevance that ADCC and other
cetuximab-mediated immune activity have in tumor control and
eradication, in particular by ‘‘priming” innate and adaptive immu-
nity, as well as by inducing a tumor microenvironment that is well
suited to further inhibition of ICIs, or to elimination of ICI-bearing
dysfunctional lymphocytes, to stimulate better adaptive, T cell–
mediated immunity.
Overall, individual patients’ basal ADCC activity, high NKp46
expression, and increased average ADCC-mediated killing have all
been shown to correlate with positive clinical outcomes, including
longer relapse-free survival, increased likelihood of response to
therapy, and prolonged overall survival [2,3,40,45].
Collectively, these observations strongly support the conclusion
that ADCC is an important component of cetuximab’s antitumor
activity; more generally, studies suggest that ADCC measurement,
monitoring, and targeting are of clinical importance during cancer
treatment of individual patients with IgG1 isotype mAbs [5,31].Markers for ADCC and related immune responses
Biological differences between tumor types can be overshad-
owed by the individual intervariability seen among patients with
a given tumor type based on factors such as disease stage, age,
genetic markers, and tumor biomarker expression. Individual
ADCC activity and CD16 receptor alleles may be predictive for clin-
ical outcomes in response to IgG1-based anticancer therapy
Table 2
Clinical and in-human, ex vivo evidence for cetuximab-mediated immune effects.
Study Indication
Bertino et al. A phase I trial to evaluate antibody-dependent cellular cytotoxicity of cetuximab and lenalidomide in advanced colorectal and head and neck
cancer. Mol Cancer Ther 2016;15(9):2244–50
CRC
Bibeau et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal
cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122–9
CRC
Chow et al. Phase 1b trial of the toll-like receptor 8 agonist, motolimod (vtx-2337), combined with cetuximab in patients with recurrent or metastatic
SCCHN. Clin Cancer Res 2016. pii: clincanres.1934.2016
SCCHN
Inoue et al. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci 2017;108(3):455–60 CRC
Jha et al. Potentiation of cetuximab by inhibition of Tregs in metastatic squamous cell cancers of head and neck. Anticancer Res 2014;34:5975–7 SCCHN
Khort et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014;124:2668–82 SCCHN
Lo Nigro et al. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal
cancer patients. World J Gastrointest Oncol 2016;8:222–30
CRC
Negri et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated
with cetuximab therapy. Pharmacogenomics J 2014;14:14–9
CRC
Rocca et al. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2or IL-15. Front
Immunol 2016;7:413
CRC
Srivastava et al. CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head
and neck cancer. Clin Cancer Res 2017;23(3):707–16
SCCHN
Direct link between ADCC and treatment outcomes
Etienne-Grimaldi et al. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with
cetuximab-irinotecan. Br J Clin Pharmacol 2012;73(5):776–85
CRC
Inoue et al. FcgammaR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther 2014;18:541–
8
CRC
Jie et al. CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor
prognosis. Cancer Res 2015;75:2200–10
SCCHN
Jie et al. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol
Res 2017;5(5):408–16. doi: 10.1158/2326-6066.CIR-16-0333
SCCHN
Lattanzio L. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict
favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. Cancer Immunol Immunother
2017 Feb 14. doi: 10.1007/s00262-017-1960-8. [Epub ahead of print]
SCCHN
Monteverde et al. The relevance of ADCC for EGFR targeting: a review of the literature and a clinically-applicable method of assessment in patients. Crit Rev
Oncol Hematol 2015;95(2):179–90
Review
Rodriguez et al. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated
metastatic colorectal cancer. Eur J Cancer 2012;48:1774–80
CRC
Trotta et al. Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity (ADCC) in metastatic colorectal cancer patients predicts
treatment efficacy. Cancer Immunol Res 2016;4:366–74
CRC
Zhang et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal
cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712–8
CRC
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baseline ADCC and EGFR expression can have a positive correlation
with the rate of complete responses in patients with LA SCCHN
who are treated with cetuximab and radiotherapy [40]. Also possi-
bly having an effect on baseline ADCC activity are KRAS mutations
(although data are conflicting with regard to directionality)
[31,51,52], presence of disease (healthy volunteers mount a greater
response than cancer patients), and polymorphisms in the CD32A
and CD16 Fc receptors [31,33,53,54]. Because increased ability to
mount an ADCC response tends to correlate with prolonged overall
survival [3,33], it is important that these differences be understood
and used to potentially guide personalized treatment decisions.
Such information is especially crucial in the first line, when the
immune system may be best poised to mount an antitumor
response (given that immune depletion often occurs following
chemotherapy) [55]. As of this writing, the CD16 polymorphism
is the best-studied biomarker for ADCC.
CD16 is not required for endogenous NK cell–mediated tumor
cell lysis, but it is necessary for IgG1-mediated ADCC [33,56], and
studies suggest that increasing the binding affinity of the Fc region
to CD16 can increase NK cell cytotoxic activity [57,58]. A CD16 Fc
receptor that has a valine (V) at codon 158 (vs a phenylalanine [F])
has a much higher binding affinity for mAbs. Therefore, patients
who carry the V/V polymorphism are more immunologically
responsive to IgG1 isotype mAb-based therapy (cetuximab, ritux-
imab, trastuzumab, etc) than patients with the F/F polymorphism;
the V/F variant appears to manifest as an affinity phenotype that is
intermediate between V/V and F/F or equal to V/V, depending on
the study [33,49,50,53,54,59]. Downstream of CD16 activation,
CD137 expression (which stimulates recruitment of EGFR-specificcytotoxic T cells to the tumor) correlated with clinical response
[44,60]. Interestingly, in an analysis of 107 patients with SCCHN
who received cetuximab, no predictive value for CD16 codon 158
polymorphism was detected for anti-EGFR therapy efficacy
(although only 13 patients had the V/V variant); another study in
49 patients with KRAS wild-type mCRC found a significant differ-
ence in outcomes among patients with different genetic variants
of CD16 [26,61]. Therefore, the predictive value of CD16 remains
to be fully confirmed.
An additional polymorphism associated with cetuximab
immune activity is found on codon 131 (histidine [H] vs arginine
[R]) of the CD32A/FccRIIa receptor on DCs and neutrophils [25];
this polymorphism helps restore tumor immune surveillance and
stimulates downstream immunogenic response. The 6-month dis-
ease control rate (DCR) was higher in patients with CRC (n = 47)
treated with cetuximab and carrying the H/H and H/R variants
(67% and 50%, respectively) vs the R/R variant (17%), despite all
patients having a mutation in KRAS, NRAS, BRAF, or PI3K (suspected
to confer resistance to cetuximab in CRC). In the same study,
patients carrying the V/V or V/F variant on CD16 (31 patients;
70% of the overall study population) had a combined 6-month
DCR of 52% vs 23% in patients carrying the F/F variant (n = 13)
[62]. Similarly, in patients with mCRC treated with cetuximab plus
irinotecan-based chemotherapy, overall survival was significantly
longer in patients carrying a 158 V genotype [63]. A meta-
analysis of studies of anti-EGFR mAb-based therapy in CRC (that
did not distinguish between cetuximab and panitumumab, a
choice that could have confounded the results) concluded that nei-
ther the CD32A nor the CD16 polymorphisms are predictive of
response during therapy [64]. It should be noted that IgG2-
R.L. Ferris et al. / Cancer Treatment Reviews 63 (2018) 48–60 53driven immune activity may be associated with polymorphisms on
CD32A [65]. Indeed, it appears that any effect of CD32A polymor-
phisms on baseline ADCC activity is due to linkage disequilibrium
rather than direct interaction [66]. Further investigation is required
to fully characterize the predictive value of CD16/32 receptor poly-
morphisms during immunomodulatory therapy.
Treg and other immunosuppressive mechanisms are triggered
in the intratumoral space as feedback mechanisms to counteract
cytotoxic tumor cell lysis [42,48,67–71]. These negative regulatory
mechanisms, detailed in the next section, could become additional
therapeutic targets when planning combination treatments with
cetuximab.Fig. 2B. Immunosuppressive mechanisms that can account for the dampening of cetuxim
of cetuximab to EGFR and to the CD16 receptor on NK and dendritic cells sets off feedback
of immune checkpoints on tumor and immune cells. CD, cluster of differentiation; CTL
ligand; CXCR, C-X-C chemokine receptor; EGFR, epidermal growth factor receptor; HLA, h
suppressor cell; NK, natural killer; PD-1, programmed death receptor 1; PD-L1, programImmune modulation of ADCC and T cells and implications for
cetuximab-based treatment
Treg
An overview of the immunosuppressive pathways activated in
response to cetuximab-mediated immunostimulation in the tumor
microenvironment is presented in Fig. 2B [42,48,67–71]. Treg
activity is one of the most powerful immunosuppressive mecha-
nisms in the intratumoral space. Compared with those of healthy
subjects, cancer patients’ peripheral blood and tumor-infiltrating
lymphocyte populations are enriched in Treg, possibly due to con-ab-mediated immune activity. Immunostimulatory activity initiated by the binding
immunosuppressive mechanisms, including Treg tumor infiltration and expression
A-4, cytotoxic T-lymphocyte-associated protein 4; CXCL, chemokine (C-X-C motif)
uman leukocyte antigen; IFNc, interferon-c; IL, interleukin; MDSC, myeloid-derived
med death-ligand 1; TGFb, transforming growth factor b; Treg, regulatory T cells.
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naling (based on preclinical and ex vivo studies) [48,67,68,72,73].
Treg secrete suppressive cytokines and express membrane-bound
TGFb, thus inhibiting the cytolytic activity of T cells and NK cells,
as well as the maturation of DCs [42,68]. Furthermore, highly
immunosuppressive Foxp3+/CTLA-4+ or PD-L1+ Treg are found to
be more concentrated in the tumor microenvironment than in
the peripheral blood [48]. In the presence of increased CD4+/
CD25hi/Foxp3+ Treg populations in the intratumoral space, NK cells
have lowered expression of biomarkers indicative of ADCC activity,
such as granzyme B, perforin, and CD16 [42,46]. In vitro and
ex vivo assays demonstrate that the addition of CD4+/CD25hi/Fox-
p3+ Treg suppress cetuximab-driven NK-mediated ADCC in
patients with SCCHN via secreted cytokines and membrane-
bound TGFb; TGFb inhibitors are sufficient to block this Treg-
mediated immune suppression in vitro [42,46,68,70,71]. Crucially,
in vitro experiments and a phase 1a clinical trial suggest that
depleting the CD4+/Foxp3+ Treg population can restore or enhance
NK cell cytotoxic activity [68,74,75].
Furthermore, it is conceivable that Treg-mediated suppression
of cetuximab-driven immune activity can potentially be a prognos-
tic factor in patients undergoing treatment with cetuximab for LA
SCCHN. Cetuximab plus chemotherapy/radiotherapy treatment in
patients with LA SCCHN (n = 22) led to a significant increase in
the frequency of CD4+/Foxp3+ Treg within lymphocyte populations
in both the peripheral blood and tumor microenvironment [42].
Furthermore, 4 weeks of cetuximab monotherapy (n = 18 patients)
appeared to increase the frequency of intratumoral CD4+/Foxp3+
Treg expressing markers of immunosuppression such as CTLA-4,
CD39, and membrane-bound TGFb. Peripheral CD4+/Foxp3+ Treg
were significantly enriched in CTLA-4, possibly indicating a
response to cetuximab-driven immunostimulation (and by exten-
sion the conversion of an immunologically ‘‘cold” tumor to a ‘‘hot”
phenotype) [25,42]. When comparing the frequency of Treg in both
the periphery and the intratumoral space in clinical responders to
cetuximab with that of nonresponders, Jie et al. found that respon-
ders have stable Treg populations, while nonresponders have sig-
nificant increases in CTLA-4+ Treg within both the peripheral
blood and tumor-infiltrating lymphocyte populations [42]. Similar
observations regarding the correlation between Treg recruitment
to the tumor microenvironment and lower patient survival have
been made across multiple tumor types [72,76]. Interestingly,
specifically in CRC, tumor-infiltrating Treg can have high (suppres-
sive) vs low (nonsuppressive) Foxp3 expression, and the presence
of the latter may be a positive prognostic biomarker of immune
response [77]. Overall, it appears that cetuximab-driven ADCC
and other immune activity initiate a negative feedback loop of
immunosuppression via immune checkpoints; thus, inhibition of
suppressive Treg (eg, CTLA-4+ or PD-L1+ populations) through ICI
treatment is a logical therapeutic strategy to use in combination
with cetuximab in both SCCHN and CRC [78]. In addition, experi-
mental data underline the role of the PD-1/PD-L1 axis inhibition
in the prevention of the peripherally induced Treg [79] leading to
the curtailment of this cell population into the tumor microenvi-
ronment. This fact may be of high importance considering that
Ghiringhelli et al. showed an inverse relationship between NK cell
activation and the extension of the Treg population [68].
Other immunosuppressive mechanisms impacting cetuximab-driven
immune activity
Cetuximab monotherapy results in an increased frequency of
CD107a+ and CD137+ (i.e., active) NK cells in the tumor microen-
vironment of patients with SCCHN. Interestingly, cetuximab
monotherapy also leads to an increased frequency of circulatingvs tumor-infiltrating perforin+ and granzyme B+ NK cells [42].
As perforin and granzyme B are the operative molecules of NK
cell lytic activity [45], these findings suggest that additional
immunosuppressive mechanisms are ongoing in the intratumoral
space and that these mechanisms prevent NK cells in the intratu-
moral space from mounting degranulation and tumor cell lysis.
These immunosuppressive processes are likely therapeutically
targetable in a way that would further increase the antitumor
effects of cetuximab-mediated immune activity (Fig. 2B). Evi-
dence suggests that suppressive activity also occurs in patients
with CRC. For example, the presence of CRC and its increasing
stage both correlate with higher levels of NK cells present in
the peripheral blood vs the intratumoral space; activating recep-
tors such as NKG2D and NKp46 are decreased in expression on
NK cells from patients with CRC vs healthy donors [45]. Blocking
the immunosuppressive receptor CD32B on DCs, or incubation
with IL-2 or IL-15, has been shown to alleviate some of this inhi-
bition on NK lytic activity [22,25,45], and this strategy may there-
fore be useful in combination with cetuximab treatment in
SCCHN and CRC.
Myeloid-derived suppressor cells (MDSCs) are another cell pop-
ulation considered an important hurdle in immunotherapy [69,80].
Their numbers increase in cancer patients vs healthy volunteers
[69], and they encourage tumor immune escape by expressing high
levels of TGFb and producing IL-10 in the tumor microenviron-
ment, its periphery, or the lymph node tissue [81]. Additionally,
myeloid-derived cytokines suppress antitumor activity of T cells
via C-X-C motif chemokine receptors (CXCR3 and 4, for example)
[82,83]. Interestingly, the disinhibition of T cells via anti–PD-1
therapy initiates a negative feedback loop, stimulating myeloid cell
production of PD-L1 and subsequent T cell reinhibition [82]. These
observations suggest that ICI therapy is a good candidate to coun-
ter MDSC-mediated suppression of cytotoxic cells via PD-1/PD-L1
in the tumor microenvironment. Like Treg, MDSC development,
expansion, and function can be guided by a variety of factors
[84,85].
IFNc is secreted by NK cells in response to the presence of cells
coated with cetuximab and stimulates the maturation of DCs; in
addition to priming cytotoxic T cells, DCs reciprocally activate NK
cells to induce more IFNc secretion. The blocking of IFNc with a
neutralizing mAb prevents crosstalk between NK cells and DCs
[25,26], revealing potentially relevant mechanisms for immune
escape. Incubation of human NK cells in the presence of TGFb also
suppresses CD16-mediated IFNc secretion, and extended treat-
ment inhibits ADCC via reduction of granzymes A and B [86]. In
addition, IFNc can signal via signal transducer and activator of
transcription 1 (STAT1) and human leukocyte antigen (HLA) class
I to further stimulate cytotoxic T cell activity [87]; defects in this
pathway have been associated with impaired T cell–mediated lysis
[88], and maintaining HLA class I levels during therapy has been
correlated with improved clinical responses to cetuximab-based
therapy in patients with SCCHN [87]. Interestingly, EGFR activity
works to suppress this pathway, hence facilitating tumor immune
escape. HLA class I can thus be upregulated via cetuximab’s EGFR-
inhibitory activity [87]. Therefore, cetuximab is a logical therapy in
that it simultaneously promotes IFNc secretion and EGFR blockade,
both of which are processes that can counteract EGFR-mediated
immunosuppression in the tumor microenvironment [87,89,90].
Finally, EGFR signaling and, interestingly, IFNc aid in tumor
immune escape by stimulating PD-L1 expression on tumor cells
through the Janus kinase 2 (JAK2)/STAT1 pathway, thus inhibiting
active T and NK cells in a PD-1/PD-L1–dependent manner [27,91].
Thus, cetuximab treatment could be useful in potentially priming
tumors for better T cell recognition, which would then be
enhanced with ICIs.
R.L. Ferris et al. / Cancer Treatment Reviews 63 (2018) 48–60 55Optimizing immune action: the promise of combination
between cetuximab and immunotherapy
Cetuximab has demonstrated clinically meaningful activity in
both SCCHN and RAS wild-type mCRC; it is a vital component of
the standard of care for both indications in the unresectable
setting, and it yields favorable outcomes in clinical trials and in
the real-world setting [35,38,92–95]. Furthermore, cetuximab
promotes high response rates as evidenced by its addition to prior
standard-of-care treatments (e.g., radiotherapy, chemotherapy),
which has led to enhanced ORRs and prolonged survival. In addi-
tion to the benefits associated with EGFR inhibition, cetuximab-
mediated ADCC and the recruitment and priming of cytotoxic T
cells to the intratumoral space are powerful attributes. However,
as described above, such immunostimulation is necessarily associ-
ated with negative feedback loops (Treg, MDSCs, and increasedFig. 2C. Mechanisms of synergy between cetuximab and ICIs (or other immunotherap
immune effector cells present in the intratumoral space. CD, cluster of differentiation
receptor; EGFR, epidermal growth factor receptor; IFNc, interferon-c; IL, interleukin; M
receptor 1; PD-L1, programmed death-ligand 1; TGFb, transforming growth factor b; Treexpression of checkpoint molecules such as PD-1, PD-L1, and
CTLA-4). Therefore, co-targeting of these immunosuppressive pro-
cesses, and the potential synergy between the different mecha-
nisms of action of cetuximab and ICIs, holds the potential to
improve patient outcomes in SCCHN and CRC. For example,
CTLA-4 or PD-1/PD-L1 blockade has the potential to alleviate
Treg- or MDSC-mediated inhibition on both T cells and NK cells,
thereby restoring cytotoxic activity and fully mobilizing the adap-
tive and innate immune systems against tumor cells [96–99],
because many of these immunosuppressive mechanisms impinge
upon negative regulation of T cells and NK cells via PD-1, PD-L1,
or CTLA-4 (Fig. 2C) [13,27,47]. As further evidence in favor of this
combination of drugs, cetuximab recruits new immune cells to
the tumor microenvironment, whereas ICIs disinhibit cells already
present. Thus, cetuximab and ICIs complement each other, and
cetuximab could serve to prime the immune system in preparationies). ICIs may synergize with cetuximab-driven immune activity by disinhibiting
; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR, C-X-C chemokine
DSC, myeloid-derived suppressor cell; NK, natural killer; PD-1, programmed death
g, regulatory T cells.
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result of) ICI therapy, raising the possibility of true synergistic
activity via complementary activation of the innate and adaptive
immune systems and the engagement of multiple types of immune
cells. Although the known safety profiles of cetuximab and ICIs do
not appear to overlap, minimal safety and efficacy data are cur-
rently available from trials of cetuximab and ICI combinations.
Studies assessing acute and late toxicities of cetuximab and ICI
combinations are currently ongoing. On the other hand, com-
pounding of toxicities has been observed in ICI plus ICI combina-
tion treatments, with which additive immune-related adverse
events can be severe and may preclude the widespread use of
dual-ICI therapy [100,101]. Next, we outline the biological ratio-
nale for the combination of cetuximab, a logical combination part-
ner due to its various immunostimulatory effects, with emerging
immunotherapies in SCCHN and mCRC (cetuximab’s approved
indications for use), placing special focus on ICIs.
Patients with SCCHN are good candidates for powerful
immunostimulatory therapy, because such cancers’ possible meth-
ods of origin are associated with an immunologically ‘‘hot” pheno-
type [8,13,102–106]. Additionally, the common use of
radiotherapy in LA SCCHN provides a unique opportunity to com-
bine the radiosensitizing properties and immunostimulatory activ-
ity of cetuximab with T cell disinhibition as well as the
hypothesized abscopal effect with ICIs [21]. Additionally, the com-
bination of cetuximab and avelumab (an anti–PD-L1 IgG1 isotypeTable 3
Key ongoing clinical trials of cetuximab plus another immunotherapy.
Study Indication Arms
NCT02764593
(Phase 1)
LA SCCHN Nivolumab + cisplatin
Nivolumab + high-dose cisplatin
Nivolumab + cetuximab
Nivolumab + IMRT
NCT02124850
(Phase 1)
LA SCCHN (stage
II-IVA)
Motolimod + cetuximab
Motolimod + cetuximab + nivolumab
NCT01860430
(Phase 1b)
LA SCCHN (stage
III-IVB)
Cetuximab/IMRT + ipilimumab
NCT01935921
(Phase 1)
High-risk LA
SCCHN (stage III-
IVB)
Cetuximab/IMRT + ipilimumab
NCT02938273
(Phase 1)
LA SCCHN (stage
III-IV)
Cetuximab/RT + avelumab
NCT02999087
(Phase 3
REACH trial)
LA SCCHN (stage
III-IVb)
Cetuximab/RT + avelumab vs Cisplatin/RT
(fit patients) OR cetuximab/RT (unfit
patients)
NCT03051906
(Phase 1b
DUCRO HN)
LA SCCHN Cetuximab/RT + durvalumab
NCT02643550
(Phase 1, 2)
Pretreated R/M
SCCHN
Cetuximab + monalizumab
NCT02318901
(Phase 2)
Advanced SCCHN
Advanced mCRC
(KRAS/BRAF/NRAS
wt)
Pembrolizumab + cetuximab
NCT02713373
(Phase 1/2)
Unresectable
mCRC
Pembrolizumab + cetuximab
NCT03174405
(Phase 2
AVETUX-AIO
KRK 0216)
Untreated mCRC
(RAS/BRAF wt)
Avelumab + cetuximab + FOLFOX
IMRT, intensity-modulated radiotherapy; LA SCCHN, locally advanced squamous cell c
response rate; OS, overall survival; PFS, progression-free survival; R/M SCCHN, recurrent
wt, wild-type.mAb) is of high interest due to both agents’ ability to stimulate
ADCC, because the use of 2 ADCC-inducing mAbs could potentially
generate a beneficial immune effect by priming and activating NK
cells cooperatively.
Although CRC has traditionally been considered an immunore-
sistant cancer, prognostic factors such as high basal ADCC activity
and the presence of tumor-infiltrating T cells suggest this pre-
sumption is inaccurate [2,24,107]. However, individual tumor
molecular subtypes may be differentially susceptible to ICI
monotherapy, and thus far only microsatellite-unstable tumors
have shown responses to such an approach [108–110], likely
because of their tendency to produce neoantigens. Therefore,
research into combination therapy with ICIs plus an agent with
already-proven activity in mCRC (i.e., cetuximab) is necessary to
determine whether such a combination regimen would possess
activity in non-microsatellite-unstable tumors.
Consequently, although CRC and SCCHN are very different dis-
eases, cetuximab plus ICIs may still result in additive activity in
CRC tumors by priming them for immunotherapy (e.g., by inducing
PD-1/PD-L1 expression on immune cells and by recruiting immune
effector cells to the tumor). Additionally, cetuximab can mediate
increased immune activity within the tumor microenvironment
(e.g., drive crosstalk between NK cells and DCs and recruit cyto-
toxic T cells to the tumor microenvironment) [19,23–28], thus
priming the immune system to be more responsive to ICI treat-
ment. Reciprocally, in vitro research on this combination suggestsEndpoints Institution
Dose-limiting toxicity Radiation Therapy Oncology Group
Change in immune biomarkers
Antitumor response
University of Pittsburgh Medical
Center
Determining starting dose
Clinical response, PFS, potential
biomarkers
University of Pittsburgh Cancer
Center
Determining starting dose
Clinical response, PFS, potential
biomarkers, dose response
National Cancer Institute
Safety
ORR, changes in tumor
microenvironment
The Netherlands Cancer Institute
PFS
OS, safety
Groupe Oncologie Radiothérapie
Tête et Cou
PFS
Safety
Azienda Ospedaliero-Universitaria
Careggi
Safety
ORR
University of Pennsylvania
Determining recommended dose
Safety, ORR, OS, PFS, changes in
circulating DNA
Western Regional Medical Center/
Cancer Treatment Center of
America
Safety, PFS, tumor response rate
ORR, OS, changes in blood biomarkers
and tumor-immune cell populations
Roswell Park Cancer Institute
Safety, ORR, PFS, OS, translational
research
AIO-Studien-gGmbH
arcinoma of the head and neck; mCRC, metastatic colorectal cancer; ORR, overall
and/or metastatic squamous cell carcinoma of the head and neck; RT, radiotherapy;
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such as that mediated by mutations in RAS and other genes [43].
Although we have focused on ICIs, cetuximab-mediated
immune action drives crosstalk with a variety of immune cell types
and processes, and therefore it holds the potential for combination
with many additional classes of immunotherapy. From ex vivo
studies in CRC, combination treatment with cetuximab plus cytoki-
nes such as IL-2 or IL-15 was sufficient to restore the lytic activity
of patient-derived NK cells to levels comparable to those of healthy
donors [45]. Similarly, in SCCHN, cotreatment with cetuximab and
urelumab (a CD137-agonist mAb) in a phase 1b trial led to
increased levels of granzyme B and NKp46 on NK cells, although
there were no changes in IFNc, PD-1, CD107a, NKG2D, or CD16
[44]. As mentioned earlier in this review, CD137 is a possible mar-
ker for clinical response, and urelumab treatment has been shown
to lead to increased IFNc-driven gene expression and cytokine pro-
duction and overall enhanced immunologic activity [111]. Further-
more, cetuximab in combination with cytokines or urelumab was
also able to exert immune activity on EGFR-expressing CRC cell
lines or xenograft models despite the presence of a KRAS, NRAS,
or BRAF mutation [43,45,60]. Similar observations have been made
for cetuximab in triple-negative breast cancer xenografts and KRAS
mutant cell lines [112,113].
Additional non-ICI agents currently in clinical trials in combina-
tion with cetuximab include monalizumab (IPH2201), an anti-
NKG2A mAb that blocks this inhibitory receptor on NK cells in R/M
SCCHN (NCT02643550). This combination would stimulate ADCC,
inhibit the EGFR, and simultaneously disinhibit NK cells suppressed
via TGFb or IL-10. Motolimod, a toll-like receptor–8 agonist, is being
tested in combinationwith cetuximab for patients with R/M SCCHN
(NCT01836029) and has some available early results indicating a
DCR of 54% and increases in circulating cytokines [1]. Combination
motolimod plus cetuximabwith orwithout nivolumab is now being
tested in patients with LA SCCHN (NCT02124850). Other combina-
tions include systemic immunomodulation via heat-killed
mycobacteria (IMM-101, NCT03009058), DNA demethylation via
valproic acid (NCT02624128) that has been shown topossess antitu-
mor effects in other indications [114], and stimulation of neutrophil
growth and activity with granulocyte-colony stimulating factor
(NCT02124148). Finally, several trials are investigating ex vivo–
grown and –activated immune cells, including NK and CD4+ or
CD8+ T cells, in combination with cetuximab (NCT02028455,
NCT02507154) across indications. Therapies for additional novel
targets, such as CXCR4 activation, MDSC inhibition, and TGFb traps,
will likely compose the next wave of combination therapies.
Key ongoing trials of cetuximab and ICI combination therapy in
CRC and SCCHN are summarized in Table 3.Conclusions and future outlook
ICI monotherapy is a new and exciting treatment option, but
response rates are modest in some indications, including SCCHN
and CRC. Fortunately, there is a strong scientific rationale for com-
bining ICIs and the existing standard-of-care mAb cetuximab for
the treatment of advanced SCCHN and CRC. In addition to EGFR
inhibition, cetuximab mediates clinically relevant ADCC and other
immune activity in the intratumoral space, which is associated
with tumor cell killing by components of both the innate and adap-
tive immune systems. Cetuximab can prime the immune system
for ICI therapy by recruiting cytotoxic cell effectors of both the
innate and adaptive immune systems to the intratumoral space.
Additionally, associated negative feedback loops lead to CTLA-4/
PD-1/PD-L1–mediated immunosuppression of active cytotoxic cell
types, an issue that ostensibly could be overcome successfully via
combination therapy with ICIs. Indeed, in some situations suchas non-small cell lung cancer, it has been shown that strong PD-
(L)1 expression is associated with better outcomes when treated
with anti–PD-(L)1. In the case of cetuximab plus avelumab, ongo-
ing prospective studies will evaluate whether using 2 ADCC-
inducing mAbs will generate a beneficial immune effect by priming
and activating NK cells cooperatively. More generally, by synergis-
tically and fully mobilizing the adaptive and innate immune sys-
tems against tumor cells, cetuximab in combination with ICIs or
other immunotherapies could hold the key to raising ORRs and
durability of response in challenging indications such as SCCHN
and CRC. Empirical evidence from currently ongoing clinical trials
that are evaluating this hypothesis is eagerly anticipated.Disclosures
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